Inger Sandlie

This inventor holds 19 USPTO granted patents and 29 published patent applications, plus 4 CIPO patents and 9 EPO patents, primarily in Engineered Immunoglobulins. Top assignees: University of Oslo, Vaccibody as, Albumedix Limited. Active years: 1994-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Inger Sandlie. Retrieved from https://idiyas.com/inventor/inger-sandlie

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 29)

% Patents Active = 94.7

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 9 (Patent Applications = 15)

Average Co-Inventor Count = 3.4

ph-index = 6

Forward Citations = 214(Granted Patents)

Company Filing History:

Novozymes Biopharma Dic A/s

patent

9. 1 out of 16

Novozymes Biopharma Dk A/s

11. 1 out of 834,570

Other

patents

Years Active: 1994-2026

Loading Chart...

Areas of Expertise:

Immunoglobulins

FcRn Binding

Antibody Variants

Albumin Derivatives

Phage Display

MHC Class II

Modified Antibodies

Multivalent Systems

Disulphide Bonds

IgG3 Antibodies

Vector Constructs

Functional Molecules

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12674004 - ENGINEERED IMMUNOGLOBULINS WITH ALTERED FCRN BINDING (2026-07-07),

2. 11999781 - Antibody variants (2024-06-04),

3. 11319383 - Engineered immunoglobulins with altered FcRn binding (2022-05-03),

4. 11306318 - Vector construct (2022-04-19),

5. 10781245 - Albumin variants and uses thereof (2020-09-22),

6. 10696732 - Albumin variants (2020-06-30),

7. 10640761 - Multivalent phage display systems and methods (2020-05-05),

8. 10233228 - Albumin derivatives and variants (2019-03-19),

9. 10208102 - Albumin variants and uses thereof (2019-02-19),

10. 9796787 - Modified antibody (2017-10-24),

11. 9598692 - Multivalent phage display systems and methods (2017-03-21),

12. 9169322 - Modified antibody (2015-10-27),

13. 9056920 - Disulphide bond-stabilized functional soluble MHC class II heterodimers (2015-06-16),

14. 8932603 - Modified antibody (2015-01-13),

15. 8828379 - Disulphide bond-stabilized functional soluble MHC class II heterodimers (2014-09-09),

Title: Inventor Spotlight - Inger Sandlie

Introduction: Inger Sandlie is a pioneering inventor based in Oslo, Norway, known for her groundbreaking contributions to the field of biotechnology and medical research.

Latest Patents: Inger Sandlie holds several patents related to innovative biotechnological solutions for healthcare, including novel drug delivery systems and diagnostic tools.

Career Highlights: With a distinguished career spanning over two decades, Inger Sandlie has been at the forefront of developing cutting-edge technologies that have revolutionized the medical industry. Her work has significantly impacted the way diseases are diagnosed and treated.

Collaborations: Throughout her career, Inger Sandlie has collaborated with leading research institutions, pharmaceutical companies, and medical professionals to bring her inventions from concept to reality. Her collaborative spirit has been instrumental in the successful implementation of her innovative ideas.

Conclusion: In conclusion, Inger Sandlie's relentless pursuit of innovation and her passion for improving healthcare have established her as a prominent figure in the world of biotechnology. Her contributions continue to inspire the next generation of inventors and researchers in the field.

Profile summary based on public USPTO records.